Pheon Therapeutics

Pheon Therapeutics is a clinical-stage biotechnology company developing a pipeline of antibody-drug conjugates for the treatment of solid tumours.

The company combines monoclonal antibodies with proprietary cytotoxic payloads and linker technologies, taking a target-specific approach to optimising each construct for safety and efficacy.

Its lead programme is a first-in-class ADC directed at a widely overexpressed solid tumour antigen, with additional programmes addressing the same target with distinct linker-payload combinations.